Life Sciences

2024 Top-of-Mind Issues for Life Sciences Companies

By Scott Liebman, Jeffrey Fessler, Dominick DiSabatino, A. Joseph Jay, III, Erica Kraus, Bevin Newman, Lorna Tanner, Eve Costopoulos, Keren Baruch, Audrey Mercer, Cortney Inman, Julia Kadish, Nathan Lee, Justine Lei, Yang Li, Arushi Pandya, Tom Reklaitis & Juaniece Rainey* on January 25, 2024

Posted in Life Sciences, Top-of-Mind Issues

As we reflect on 2023 and make predictions for 2024, it is remarkable the number of significant events occurring this past year that will be impactful for the activities of the life sciences industry going forward. Although there was no single moment like the passage of the Affordable Care Act in 2010, there are numerous distinct events that will loom large in 2024 and beyond.Continue Reading 2024 Top-of-Mind Issues for Life Sciences Companies

2023 Top-of-Mind Issues for Life Sciences Companies

By Scott Liebman, Christine Clements, Dominick DiSabatino, Jeffrey Fessler, A. Joseph Jay, III, Eve Costopoulos, Audrey Mercer, Julia Kadish, Alexandra Kitson, Justine Lei, Seth Lemings, Arushi Pandya & Cortney Inman on January 11, 2023

Posted in Life Sciences, Top-of-Mind Issues

The Sheppard Mullin Life Sciences Team decided to take a different approach to our year-end review. We surveyed and considered issues most important to our clients, asking the experts across the various specialties in our Life Sciences Practice the following question: What do life sciences companies need to keep top of mind in 2023?Continue Reading 2023 Top-of-Mind Issues for Life Sciences Companies

Menu

FDA Law Update

Life Sciences

2024 Top-of-Mind Issues for Life Sciences Companies

2023 Top-of-Mind Issues for Life Sciences Companies

FDA Law Update

About The Firm